For decades, Alzheimer’s disease research has largely focused on the role of amyloid beta (Aβ), a protein that forms plaques in the brain. Billions of dollars have been invested in therapies targeting Aβ, yet a truly effective treatment remains elusive. Now, a growing body of research suggests a previously overlooked peptide, known as P3, may be a critical piece of the puzzle—and could explain why so many Alzheimer’s drug trials have failed. Understanding the role of P3 in Alzheimer’s disease could fundamentally shift the direction of research and treatment strategies for this devastating condition.
A new commentary published in the journal ChemBioChem by Jevgenij Raskatov, a biochemist at the University of California, Santa Cruz, details how P3 forms toxic clumps even faster than Aβ and may contribute to neurodegeneration. Raskatov’s work challenges the long-held assumption that P3 is harmless and readily dissolves in the brain. He argues that this misconception has hindered progress in developing effective Alzheimer’s therapies.
“The P3 peptide is, most likely, not the innocent bystander it was commonly thought to be,” Raskatov stated. “There’s still more research to be done. But this could turn Alzheimer’s research on its head.” His lab’s research demonstrates that P3 is capable of forming amyloid deposits and exhibits neurotoxic properties, albeit to a lesser extent than Aβ.
The Limitations of Focusing Solely on Amyloid Beta
Alzheimer’s disease affects approximately 35 million people worldwide and carries an annual cost exceeding $800 billion, with projections indicating a doubling of cases by 2050. Despite the significant investment, over 400 clinical trials targeting Aβ have largely failed or yielded only modest benefits, sometimes accompanied by serious side effects like hemorrhages and strokes. Current treatments, such as cholinesterase inhibitors and NMDA receptor antagonists, primarily manage symptoms without halting disease progression. Newer antibody therapies like Lecanemab and Donanemab aim to clear Aβ from the brain, but their success has been limited.
Both Aβ40 and Aβ42, peptides formed from the Amyloid Precursor Protein (APP) through sequential cleavage by β-secretase and γ-secretase, have been central to Alzheimer’s research. Aβ42, being more prone to aggregation and toxicity, has been the primary therapeutic target for decades. However, Raskatov’s research suggests that focusing exclusively on Aβ may be a misdirection.
P3: A Newly Recognized Player
P3, also known as amyloid β-peptide (Aβ)17–40/42, is produced when APP is cleaved by α-secretase and then γ-secretase. Raskatov refers to this isoform as “Amyloid α” (Aα) to distinguish it from Aβ. Previous studies incorrectly assumed P3 was non-toxic and water-soluble, leading to its dismissal as irrelevant to the disease process. According to Wikipedia, P3 can be found as a 24 or 26 residue peptide, depending on gamma secretase’s cleavage.
Raskatov’s lab has published multiple studies over the past five years demonstrating that P3 can form amyloid deposits as rapidly as, if not faster than, Aβ. These findings have been corroborated by an independent laboratory in the United Kingdom and further research is emerging to explore the interactions between Aβ and Aα. This suggests a more complex picture of Alzheimer’s pathology than previously understood.
Challenging Established Dogma
David Teplow, an emeritus professor of neurology at UCLA, emphasized the significance of Raskatov’s work, noting that the long-held belief in Aβ as the sole culprit is now being challenged. “This reevaluation has far-reaching consequences for both basic science and clinical research into the causes and treatment of Alzheimer’s disease,” Teplow said.
Raskatov expressed concern over the persistence of misinformation in the scientific literature, citing instances where his lab’s findings were misinterpreted in published articles as evidence that P3 is innocuous. “This is exactly the opposite of what we have actually shown,” he said. “We remain in the dark on how this sort of grand confusion may have arrive about. Clearly, there is more work ahead of us.”
The implications of these findings are substantial. If P3 plays a significant role in Alzheimer’s disease, current therapies focused solely on Aβ may be insufficient. Future research will need to explore strategies to target both Aβ and P3, or to understand how they interact to drive disease progression.
Researchers are continuing to investigate the mechanisms by which P3 contributes to neurotoxicity and its potential interactions with Aβ. The next steps involve further elucidating the structure and function of P3, as well as developing novel therapeutic approaches that address both peptides. The scientific community is now grappling with the need to re-evaluate decades of research and potentially redefine the landscape of Alzheimer’s disease treatment.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
What are your thoughts on this new research? Share your comments below, and please share this article with anyone who may be affected by Alzheimer’s disease.
